Impact of Rotavirus Vaccination on Hospitalisations in Belgium: Comparing Model Predictions with Observed Data

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Standaert, Baudouin ^a   Gomez, Jorge A ^b   Raes, Marc ^c   Debrus, Serge ^a   Velázquez, F Raúl ^d   Postma, Maarten J ^e  

^a GSK   (Belgium)

^b GlaxoSmithKline   (Argentina)

^c JESSA HOSPITAL   (Belgium)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

AGE DISTRIBUTION; ARTICLE; BELGIUM; CHILD; CHILD HOSPITALIZATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; GASTROENTERITIS; HUMAN; OBSERVATIONAL STUDY; PREDICTION; PRESCHOOL CHILD; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; ROTAVIRUS INFECTION; SENSITIVITY ANALYSIS; VACCINATION;

BELGIUM; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MODELS, STATISTICAL; ROTAVIRUS; ROTAVIRUS INFECTIONS; VACCINATION;

ROTAVIRUS;

EID: 84872529744     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053864     Document Type: Article

References (29)

1. Standaert B, Parez N, Tehard B, Colin X, Detournay B, (2009) Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy 6: 199-216.
2. Martin A, Batty A, Roberts JA, Standaert B, (2009) Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 27: 4520-4528.
3. Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, et al. (2011) Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 11: 462.
4. Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, et al. (2009) The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine 27: 6121-6128.
5. Dewar DM (2009) Essentials of Health Economics. 1st ed. Burlington, MA: Jones & Bartlett Learning.
6. Garnett GP, (2002) An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 78: 7-12.
7. Atchison C, Lopman B, Edmunds WJ, (2010) Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 28: 3118-3126.
8. Atkins KE, Shim E, Pitzer VE, Galvani AP, (2012) Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 30: 552-564.
9. Lopman BA, Curns AT, Yen C, Parashar UD, (2011) Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 204: 980-986.
10. Van Effelterre T, Soriano-Gabarro M, Debrus S, Newbern EC, Gray J, (2010) A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 138: 884-897.
11. Desselberger U, Huppertz HI, (2011) Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis 203: 188-195.
12. Velazquez FR, (2009) Protective effects of natural rotavirus infection. Pediatr Infect Dis J 28: S54-S56.
13. Bilcke J, Beutels P, (2009) Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 27: 281-297.
14. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, et al. (2007) Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370: 1757-1763.
15. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B, et al. (2010) Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 362: 299-305.
16. do Carmo GM, Yen C, Cortes J, Siqueira AA, de Oliveira WK, et al. (2011) Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med 8: e1001024.
17. Tate JE, Cortese MM, Payne DC, Curns AT, Yen C, et al. (2011) Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 30: S56-S60.
18. Raes M, Strens D, Vergison A, Verghote M, Standaert B, (2011) Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 30: 120-125.
19. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H, (2010) Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 29: 319-323.
20. Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, et al. (2011) Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr Infect Dis J 30: S11-S15.
21. Raes M, Strens D, Vergison A, Verghote M, Standaert B. (2011) Third year post-rotavirus vaccination in Belgium: impact on rotavirus-positive stool samples in hospitalised children. Presented at European Society for Paediatric Infectious Diseases (ESPID) 29th annual meeting, The Hague, Netherlands, 7-11 June 2011. Available: http://www.kenes.com/espid2011/cd/pdf/O118.pdf. Accessed 2012 Jun 15.
22. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, et al. (2011) Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 30: S25-S29.
23. Fruytier A, Van Schoor J, Standaert B, (2006) Vaccination with RIX4414 is cost-effective in a Belgian setting (abstract PIH3). Value Health 9: A253.
24. Melliez H, Boelle PY, Baron S, Mouton Y, Yazdanpanah Y, (2005) Morbidite et cout des infections a rotavirus en France [Morbidity and cost of rotavirus infections in France]. Med Mal Infect 35: 492-499.
25. Standaert B, Harlin O, Desselberger U, (2008) The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J 27: S20-S27.
26. Harris JP, Jit M, Cooper D, Edmunds WJ, (2007) Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 25: 3962-3970.
27. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, et al. (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354: 23-33.
28. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, et al. (1996) Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335: 1022-1028.
29. Fischer TK, Valentiner-Branth P, Steinsland H, Perch M, Santos G, et al. (2002) Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa. J Infect Dis 186: 593-597.